Patents Examined by Chun W Dahle
  • Patent number: 10815289
    Abstract: Provided are: an Fc-binding protein having improved stability, particularly to heat and acid; a method for producing the protein; an antibody adsorbent using the protein; and a method for separating the antibodies using the adsorbent. Specifically provided are: an Fc-binding protein having improved stability to heat and acid, achieved by substituting an amino-acid residue in a specific position in the extracellular region of human FcyRIIIa with another specific amino acid; a method for producing the protein; an antibody adsorbent using the protein; and a method for separating the antibodies using the adsorbent.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: October 27, 2020
    Inventors: Yoshiharu Asaoka, Toru Tanaka, Yosuke Terao, Naoki Yamanaka, Natsuko Kizu, Masaru Aoki, Teruhiko Ide
  • Patent number: 10766960
    Abstract: The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: September 8, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Futa Mimoto, Hitoshi Katada, Hirotake Shiraiwa
  • Patent number: 10759867
    Abstract: Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 1, 2020
    Assignee: GENMAB B.V.
    Inventors: Paul Parren, Frank Beurskens, Rob N. De Jong, Aran Frank Labrijn, Janine Schuurman
  • Patent number: 10752695
    Abstract: The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Genmab A/S
    Inventors: Jan Van De Winkel, Tom Vink, Janine Schuurman, Paul Parren, Rob Aalberse, Marijn Van Der Neut Kolfschoten
  • Patent number: 10745463
    Abstract: Means for improving the effector functions of current immunotherapeutic antibodies through targeted hyper-glycosylation of the antibody Fc region are disclosed, as well as antibody variants having hyper-glycosylated Fc regions. Fc receptor-mediated effector functions have been shown to be a critical contributor to the efficacies of numerous therapeutic antibodies currently in clinical use. Targeted hyper-glycosylation of antibodies has the potential to significantly improve current immunotherapies for cancer.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: August 18, 2020
    Inventors: Eric J. Sundberg, Beatriz Trastoy Bello
  • Patent number: 10711069
    Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?RInhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 14, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Jeffrey B. Stavenhagen, Scott Koenig
  • Patent number: 10676526
    Abstract: The present invention features antibodies that have high binding affinity to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 9, 2020
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Marilyn Kehry, David J. King, Leona E. Ling, James Meador, III, Sucharita Roy, Anthony Manning
  • Patent number: 10626182
    Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: April 21, 2020
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
  • Patent number: 10613099
    Abstract: The present invention describes the generation of an anti-idiotype single-chain Fv (scFv) antibody specific for the murine (RFB4), chimeric (SM03) and humanized (SM06) versions of an anti-CD22 antibody (“the anti-CD22 antibodies”). The present invention further describes the construction of a murine IgG2a/kappa immunoglobulin carrying the variable region sequences of the anti-idiotype scFv sequences. Additionally, the present invention provides a cell line capable of producing an anti-idiotype murine antibody specific for “the anti-CD22 antibodies.” The present invention is directed against a method for identifying and evaluating the activities and concentration of “the anti-CD22 antibodies.” Additionally, the present invention provides a method for evaluating serum concentration of “the anti-CD22 antibodies” that are being used clinically. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses in patients treated with “the anti-CD22 antibodies.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 7, 2020
    Assignee: Sinomab Bioscience Limited
    Inventor: Shui-on Leung
  • Patent number: 10611817
    Abstract: The present invention addresses the first problem of providing an Fc-binding protein having improved stability, especially stability to heat and acid, of the Fc-binding protein, a method for producing this protein, and an antibody adsorbent using this protein. The present invention also addresses the second problem of providing a method that makes it possible to identify the presence or absence of glycosylation of an antibody, and a material to be used in this method. The first problem is solved by an Fc-binding protein having improved stability to heat and acid obtained by substituting amino acid residues at specific positions in the extracellular domain within human Fc?RIIIa with other specific amino acids, a method for producing this protein, and an antibody adsorbent using this protein. The second problem is solved by using an adsorbent capable of specifically adsorbing an antibody having a sugar chain, the adsorbent being obtained by immobilizing human Fc?RIIIa on an insoluble carrier.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: April 7, 2020
    Inventors: Yoshiharu Asaoka, Toru Tanaka, Teruhiko Ide
  • Patent number: 10584176
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: March 10, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Patent number: 10577413
    Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralise eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-213/-213 VH and/or VL domains especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members and their use in methods of inhibiting or neutralising eotaxin, including methods of treatment or the human or animal body by therapy.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: March 3, 2020
    Assignee: Medimmune Limited
    Inventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
  • Patent number: 10570187
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 25, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Patent number: 10571468
    Abstract: The invention is directed to engineered Fc gamma receptor type III (Fc?111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: February 25, 2020
    Assignee: ONE LAMBDA, INC.
    Inventors: Jar-How Lee, Neng Jen Remi Shih, Julie Nguyen, Rui Pei
  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Patent number: 10556948
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 11, 2020
    Inventors: Mohan Srinivasan, Shrikant Deshpande, Qihong Zhao, Huadong Sun, Ginger Rakestraw, Guodong Chen, Richard Y. Huang, Steven Sheriff, Cristian Rodriguez, John P. Throup, Rose A. Dibella
  • Patent number: 10544218
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Patent number: 10544226
    Abstract: The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: January 28, 2020
    Inventors: Sung Wuk Kim, Seung Kook Park, Jae Kap Jeong, Hyea Kyung Ahn, Min Sun Kim, Eun Sun Kim, Hae-Young Yong, Dongok Shin, Yeon Jung Song, Tae Hyoung Yoo
  • Patent number: 10533055
    Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: January 14, 2020
    Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
  • Patent number: 10525129
    Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: January 7, 2020
    Assignee: University of Southampton
    Inventors: Mark Cragg, Martin Glennie, Ali Roghanian, Stephen Beers, Peter Johnson, Sean Lim, Bjorn Frendeus, Ingrid Teige